Literature DB >> 10424811

Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation.

W W Lam1, I Hatada, S Ohishi, T Mukai, J A Joyce, T R Cole, D Donnai, W Reik, P N Schofield, E R Maher.   

Abstract

Beckwith-Wiedemann syndrome (BWS) is a human imprinting disorder with a variable phenotype. The major features are anterior abdominal wall defects including exomphalos (omphalocele), pre- and postnatal overgrowth, and macroglossia. Additional less frequent complications include specific developmental defects and a predisposition to embryonal tumours. BWS is genetically heterogeneous and epigenetic changes in the IGF2/H19 genes resulting in overexpression of IGF2 have been implicated in many cases. Recently germline mutations in the cyclin dependent kinase inhibitor gene CDKN1C (p57KIP2) have been reported in a variable minority of BWS patients. We have investigated a large series of familial and sporadic BWS patients for evidence of CDKN1C mutations by direct gene sequencing. A total of 70 patients with classical BWS were investigated; 54 were sporadic with no evidence of UPD and 16 were familial from seven kindreds. Novel germline CDKN1C mutations were identified in five probands, 3/7 (43%) familial cases and 2/54 (4%) sporadic cases. There was no association between germline CDKN1C mutations and IGF2 or H19 epigenotype abnormalities. The clinical phenotype of 13 BWS patients with germline CDKN1C mutations was compared to that of BWS patients with other defined types of molecular pathology. This showed a significantly higher frequency of exomphalos in the CDKN1C mutation cases (11/13) than in patients with an imprinting centre defect (associated with biallelic IGF2 expression and H19 silencing) (0/5, p<0.005) or patients with uniparental disomy (0/9, p<0.005). However, there was no association between germline CDKN1C mutations and risk of embryonal tumours. No CDKN1C mutations were identified in six non-BWS patients with overgrowth and Wilms tumour. These findings (1) show that germline CDKN1C mutations are a frequent cause of familial but not sporadic BWS, (2) suggest that CDKN1C mutations probably cause BWS independently of changes in IGF2/H19 imprinting, (3) provide evidence that aspects of the BWS phenotype may be correlated with the involvement of specific imprinted genes, and (4) link genotype-phenotype relationships in BWS and the results of murine experimental models of BWS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424811      PMCID: PMC1734395     

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  36 in total

Review 1.  Gametic imprinting in mammals.

Authors:  D P Barlow
Journal:  Science       Date:  1995-12-08       Impact factor: 47.728

2.  Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour.

Authors:  M J Steenman; S Rainier; C J Dobry; P Grundy; I L Horon; A P Feinberg
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

Review 3.  Beckwith-Wiedemann syndrome.

Authors:  M Elliott; E R Maher
Journal:  J Med Genet       Date:  1994-07       Impact factor: 6.318

4.  Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.

Authors:  I Orlow; A Iavarone; S J Crider-Miller; F Bonilla; E Latres; M H Lee; W L Gerald; J Massagué; B E Weissman; C Cordón-Cardó
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

5.  Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse.

Authors:  I Hatada; T Mukai
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

6.  p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.

Authors:  S Matsuoka; M C Edwards; C Bai; S Parker; P Zhang; A Baldini; J W Harper; S J Elledge
Journal:  Genes Dev       Date:  1995-03-15       Impact factor: 11.361

7.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.

Authors:  M H Lee; I Reynisdóttir; J Massagué
Journal:  Genes Dev       Date:  1995-03-15       Impact factor: 11.361

8.  Disruption of imprinting caused by deletion of the H19 gene region in mice.

Authors:  P A Leighton; R S Ingram; J Eggenschwiler; A Efstratiadis; S M Tilghman
Journal:  Nature       Date:  1995-05-04       Impact factor: 49.962

9.  Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain.

Authors:  W Reik; K W Brown; H Schneid; Y Le Bouc; W Bickmore; E R Maher
Journal:  Hum Mol Genet       Date:  1995-12       Impact factor: 6.150

10.  Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15.

Authors:  S Matsuoka; J S Thompson; M C Edwards; J M Bartletta; P Grundy; L M Kalikin; J W Harper; S J Elledge; A P Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

View more
  47 in total

Review 1.  Beckwith-Wiedemann syndrome: imprinting in clusters revisited.

Authors:  E R Maher; W Reik
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

2.  The two-domain hypothesis in Beckwith-Wiedemann syndrome.

Authors:  A P Feinberg
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 3.  Clinical risk factors for gastroschisis and omphalocele in humans: a review of the literature.

Authors:  Polina Frolov; Jasem Alali; Michael D Klein
Journal:  Pediatr Surg Int       Date:  2010-08-31       Impact factor: 1.827

Review 4.  Approach to the Diagnosis of Overgrowth Syndromes.

Authors:  Mohnish Suri
Journal:  Indian J Pediatr       Date:  2015-12-18       Impact factor: 1.967

5.  Chromosome 11 segmental paternal isodisomy in amniocytes from two fetuses with omphalocoele: new highlights on phenotype-genotype correlations in Beckwith-Wiedemann syndrome.

Authors:  F R Grati; L Turolla; P D'Ajello; A Ruggeri; M Miozzo; G Bracalente; D Baldo; L Laurino; R Boldorini; E Frate; N Surico; L Larizza; F Maggi; G Simoni
Journal:  J Med Genet       Date:  2007-01-26       Impact factor: 6.318

6.  Clinical utility gene card for: Beckwith-Wiedemann Syndrome.

Authors:  Thomas Eggermann; Elizabeth Algar; Pablo Lapunzina; Deborah Mackay; Eamonn R Maher; Marcel Mannens; Irène Netchine; Dirk Prawitt; Andrea Riccio; I Karen Temple; Rosanna Weksberg
Journal:  Eur J Hum Genet       Date:  2013-07-03       Impact factor: 4.246

7.  Increased IGF-II protein affects p57kip2 expression in vivo and in vitro: implications for Beckwith-Wiedemann syndrome.

Authors:  V Grandjean; J Smith; P N Schofield; A C Ferguson-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

8.  Alternative mechanisms associated with silencing of CDKN1C in Beckwith-Wiedemann syndrome.

Authors:  N Diaz-Meyer; Y Yang; S N Sait; E R Maher; M J Higgins
Journal:  J Med Genet       Date:  2005-08       Impact factor: 6.318

9.  Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.

Authors:  Sunita K Agarwal; Carmen M Mateo; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

Review 10.  Genetic considerations in the prenatal diagnosis of overgrowth syndromes.

Authors:  Neeta Vora; Diana W Bianchi
Journal:  Prenat Diagn       Date:  2009-10       Impact factor: 3.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.